Home Meeting notice Scandion Oncology A / S: Cancellation of the extraordinary general meeting

Scandion Oncology A / S: Cancellation of the extraordinary general meeting


We hereby announce the cancellation of the scheduled extraordinary general meeting of Scandion Oncology A / S (the “Company”) on Wednesday 6 October 2021.

Following the opinion of September 21, 2021 convene an extraordinary general meeting of the Company on October 6, 2021, shareholders representing more than 5% of the share capital have requested the holding of an additional extraordinary general meeting in order to propose to the Board of Directors that it be authorized to set up a share buyback program.

The Board of Directors has not yet assessed whether it wishes to make use of such an authorization if it is approved by the general meeting.

However, following the request and for consideration, it is up to the Board of Directors to cancel and postpone the planned extraordinary general meeting.

A new invitation to an extraordinary general meeting will be convened within October 11, 2021 (14 days from the request) in accordance with article 5.7 of the Statutes Company association.

The board of directors of Scandion Oncology have since the notice September 21, 2021 received comments on a number of items relevant to the Company. Therefore, the Board will assess these contributions and present its conclusion in due course.

For more information regarding Scandion Oncology, please contact:

Bo Rode Hansen, Chairman and CEO Peter Høngaard Andersen, Chairman of the Board

Telephone: +45 3810 2017 Telephone; +45 6190 5010

Email: [email protected] Email: [email protected]

Website: www.scandiononcology.com Website: www.scandiononcology.com

The information has been submitted for publication, through the contact person indicated above, on October 4, 2021, To 8:30 a.m.

Scandion Oncology A / S is a Phase II clinical biotechnology company currently developing first-class oral adjunctive drugs for market-leading cancer therapies. As an adjunct to standard cancer therapies, it introduces an effective therapeutic approach for cancer, which is or has become resistant to anti-cancer drugs, offering the potential for improved response rate, longer survival and long-term survival. better quality of life. The first principal candidate in its category, SCO-101, is currently in clinical phase II. The Company targets resistance to cancer drugs in a variety of treatment modalities, including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on the Nasdaq First North Growth Market Sweden. Teletype: SCOL.

Västra Hamnen Corporate Finance is the Company’s Certified Advisor on the Nasdaq First North Growth Marketplace and can be contacted at [email protected] or +46 (0) 40 200 250.



(c) Decision 2021. All rights reserved., source Press Releases – English


Please enter your comment!
Please enter your name here